Semaglutide is widely described as a GLP-1 receptor agonist, but this describes what the molecule does, rather than what the molecule actually is. So, is Semaglutide a peptide? Yes. Semaglutide is a peptide-based molecule designed as an analogue of the naturally occurring human hormone GLP-1. Its structure is based on a chain of amino acids...Read More

GLOW has become a commonly used name within peptide research discussions, particularly in areas involving skin, tissue and extracellular matrix research. But the terminology can be confusing. What is GLOW peptide? Is GLOW actually one peptide, and what does a GLOW blend contain? The most important point is that GLOW is generally used as the...Read More

KLOW 80 has become an increasingly searched term within peptide research, but the name can be confusing for anyone encountering it for the first time. Common questions include: What is KLOW 80? What does KLOW 80mg mean? What is actually contained in a KLOW blend? Unlike an individual peptide such as GHK-Cu or KPV, KLOW...Read More

KPV is an unusually short peptide that appears in experimental research involving inflammatory signalling, immune responses and gastrointestinal biology. Its three-letter name raises an obvious question: What does KPV actually stand for? KPV represents the three amino acids that make up the peptide: K — Lysine P — Proline V — Valine KPV is therefore...Read More

GHK-Cu is one of the most widely studied copper-binding peptides, appearing in research involving skin biology, extracellular matrix signalling, wound-related processes and cellular responses. But its scientific name raises a simple question: What does GHK-Cu actually stand for? GHK refers to a three-amino-acid peptide made from: G — Glycine H — Histidine K — Lysine...Read More

BPC-157 has become one of the most widely discussed experimental peptides online, but its scientific history is less commonly understood. Who discovered BPC-157, where did it originate, and why was it investigated in the first place? The story of BPC-157 is closely connected with research conducted by Croatian scientists investigating a substance referred to as...Read More

BPC-157 is one of the most widely discussed experimental peptides in research communities, but its name creates an obvious question: What does BPC-157 actually stand for? BPC stands for Body Protection Compound. BPC-157 is a synthetic peptide consisting of 15 amino acids and originates from research involving a protective compound associated with gastric juice. The...Read More

Retatrutide and Tirzepatide are frequently discussed together because both belong to a newer generation of metabolic compounds designed to interact with more than one hormone receptor. But there is one fundamental difference between them: Tirzepatide targets two principal receptor pathways, while Retatrutide targets three. Tirzepatide is a dual GIP/GLP-1 receptor agonist. Retatrutide is an investigational...Read More

Retatrutide is currently in Phase 3 clinical development. That is the straightforward answer to one of the most commonly asked questions surrounding the investigational triple receptor agonist. However, Retatrutide’s clinical development programme is considerably larger than a single Phase 3 trial. Multiple Phase 3 studies are investigating Retatrutide across obesity, type 2 diabetes and several...Read More

Anyone reading early research papers, clinical trial records or scientific discussions about Retatrutide may encounter another name: LY3437943. So what exactly is LY3437943, and how is it related to Retatrutide? The simple answer is: LY3437943 is the development code used for the investigational compound now widely known as Retatrutide. The two names do not describe...Read More